Carfilzomib is an anticancer medication containing the active constituent carfilzomib. It is used to treat a type of cancer called multiple myeloma. Multiple myeloma is a cancer of a white blood cell called the plasma cell. These cells grow uncontrolled and accumulate in the bone marrow, damaging the bones and kidneys. The treatment with this medication reduces symptoms of multiple myelomas, such as bone pain, fatigue, and anemia, improving a patient's quality of life. 

Carfilzomib was approved by the FDA on July 20, 2012, as a treatment for patients with multiple myeloma who have not responded to at least two prior therapies or whose disease has progressed within 60 days of completion of the last therapy. It is often used in combination with other medications.

Carfilzomib is a medication used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow.

Carfilzomib is typically administered as an intravenous (IV) injection by a healthcare provider. The exact dosing and frequency of administration will depend on the specific condition being treated and other individual factors, such as the patient's age, weight, and overall health. If a dose is missed, it's important to contact your healthcare provider as soon as possible. Suppose the missed dose is discovered within a few hours of the scheduled time. In that case, your healthcare provider may recommend administering the missed dose as soon as possible while maintaining the usual interval between doses. However, if more than a few hours have passed since the missed dose, your healthcare provider may recommend skipping the missed dose and resuming the regular dosing schedule at the next scheduled time. Avoid double-up on doses to make up for a missed one.

The most common side effects of carfilzomib include fatigue, nausea, vomiting, diarrhea, low blood cell counts, fever, headache, difficulty breathing, cough, muscle weakness or pain, rash, and back pain. While these side effects are generally mild, some patients may experience more serious side effects, such as cardiac events like heart failure or heart attack, blood clotting disorders or bleeding, acute kidney injury, lung damage or inflammation, infections, or tumor lysis syndrome, which can occur when cancer cells break down rapidly.

One of the most important warnings associated with carfilzomib is the risk of heart-related side effects, such as heart failure, heart attack, and arrhythmias. This medication increases the risk of infections, which can be severe or life-threatening. Other potential side effects are lung-related side effects, such as shortness of breath and pulmonary hypertension, as well as kidney and liver toxicity.  It is also important to note that carfilzomib can cause fetal harm and should not be used during pregnancy.

If you have any pre-existing heart conditions or risk factors for heart disease should be closely monitored during treatment with carfilzomib, and appropriate precautions should be taken to minimize the risk of cardiac events. You will be monitored closely for signs of infection, and appropriate prophylactic medications may be prescribed to help prevent infections. Patients with pre-existing lung, kidney, or liver conditions may be at increased risk of these side effects and should be closely monitored during treatment. Women of childbearing age should use effective contraception during treatment, and men should use condoms during sexual activity to prevent pregnancy.

It is important to take the Carfilzomib as directed by a healthcare professional. Patients should also inform their doctor of any pre-existing medical conditions and any other medications they may be taking. It is important to be aware of the potential side effects and to report any concerns to your healthcare provider. Pregnant or breastfeeding women should consult their doctor before taking it, as the drug may pose a risk to the baby. There are no specific dietary restrictions for patients taking this medication. However, it is generally recommended that patients with cancer maintain a healthy and balanced diet to support their overall health and well-being. Drinking plenty of water and other fluids, such as clear broths or herbal teas, can help to prevent dehydration.

1. Amgen Limited, Electronic medicines compendium (EMC), [Revised on August 2021] [ Accessed on 13th April 2023], https://www.medicines.org.uk/emc/files/pil.5061.pdf
2. Onyx Pharmaceuticals, Inc, US Food and Drug Administration, [Revised on Feb 2019] [ Accessed on 13th April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202714s025lbl.pdf
3. Anderson KC, Munshi NC. Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders. New York: Springer; 2019.
4. Kimberly Redic; Carfilzomib: A novel agent for multiple myeloma; The Journal of Pharmacy and Pharmacology, [ Revised on Aug 2013], [Accessed on 13th April 2023] https://pubmed.ncbi.nlm.nih.gov/23837578/

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.